![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Moberg Pharma Ab (publ) | LSE:0P48 | London | Ordinary Share | SE0003613090 | MOBERG PHARMA ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.45 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
STOCKHOLM, July 30, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma. Dr Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH.
Moberg Pharma is pleased to announce the appointment of Dr Cindy Wong as Chief Medical Officer. Dr Wong brings extensive international experience in clinical development and registration of new products in a number of treatment areas including Dermatology. She has held positions as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH and Chief Medical Officer at Q-Med/Galderma, as well as senior positions at regulatory authorities in both Sweden and Australia. Dr Wong is board certified in internal medicine and clinical immunology. She is a medical graduate from the University of Adelaide and has completed postgraduate training in Internal Medicine, Clinical Immunology and Immunopathology.
"We look forward to welcoming Cindy to Moberg Pharma. She will be joining the company in a highly exciting stage as we recently completed phase 3-trials for MOB-015, where she will be adding valuable experience from the development, registration and commercialization of novel treatments", says Anna Ljung, CEO Moberg Pharma.
CONTACT:
For additional information, please contact:
Anna Ljung, CEO
telephone: +46-707-66-60-30
e-mail: anna.ljung@mobergpharma.se
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. CET on July 30th, 2020
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/moberg-pharma/r/appointment-of-chief-medical-officer-at-moberg-pharma,c3161115
The following files are available for download:
https://mb.cision.com/Main/1662/3161115/1284934.pdf | Appointment of Chief Medical Officer at Moberg Pharma |
View original content:http://www.prnewswire.com/news-releases/appointment-of-chief-medical-officer-at-moberg-pharma-301102807.html
SOURCE Moberg Pharma
Copyright 2020 PR Newswire
1 Year Moberg Pharma Ab (publ) Chart |
1 Month Moberg Pharma Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions